New daily pill aims to boost growth in kids with dwarfism
NCT ID NCT07297875
Summary
This study is testing a new daily oral drug called ABSK061 in children with achondroplasia, the most common form of dwarfism. The main goals are to see if the drug is safe and if it can help children grow taller and improve their body proportions. The study will involve up to 110 children aged 3 to under 12 years old, who will take the drug for at least 78 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACHONDROPLASIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Children's Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Contact Email: •••••@•••••
Contact
-
Chengdu Women's and Children's Central Hospital
Chengde, Sichuan, China
-
Children's Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
-
Henan Children's Hospital, Zhengzhou Children's Hospital
Zhengzhou, Henan, China
-
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Contact
Contact Email: •••••@•••••
Contact
-
West China Second University Hospital, Sichuan University
Chengdu, Sichuan, China
Contact Email: •••••@•••••
Contact
-
Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China
Contact Email: •••••@•••••
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.